Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Low-dose versus standard-dose bevacizumab for recurrent glioblastoma
ChiCTR2300076295Phase 2Recruiting
- Sponsor
- Guangdong Provincial People's Hospital
- Start
- Sep 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of bevacizumab in glioblastoma (GBM) (2 arms), sponsored by Guangdong Provincial People's Hospital. Primary endpoint: overall survival. Started Sep 2023; status: recruiting.
02
Drugs
bevacizumab
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on ChiCTR2300076295.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300076295.